Literature DB >> 10516722

Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.

P Colmenero1, P Liljeström, M Jondal.   

Abstract

The methylcholantrene-induced P815 mastocytoma tumor is derived from DBA/2 mice and expresses a weak tumor rejection antigen, P815A. The P1A gene, which encodes for the P815A antigen, is silent in most normal tissues with the exception of testis and placenta. These characteristics make P815 an interesting mouse model for the human MAGE-type tumor antigens. Recombinant Semliki Forest virus particles (rSFV) were constructed that expressed variants of the P815 antigen. Such particles, when used for vaccination, express the antigen only transiently since the viral vector is incapable of productive replication. Nevertheless, mice vaccinated with rSFV generated strong CTL responses and were protected against P815 tumor challenge.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516722     DOI: 10.1038/sj.gt.3301004

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  14 in total

1.  HY-Specific Induced Regulatory T Cells Display High Specificity and Efficacy in the Prevention of Acute Graft-versus-Host Disease.

Authors:  Jun Li; Jessica Heinrichs; Kelley Haarberg; Kenrick Semple; Anandharaman Veerapathran; Chen Liu; Claudio Anasetti; Xue-Zhong Yu
Journal:  J Immunol       Date:  2015-06-05       Impact factor: 5.422

2.  Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.

Authors:  Francesca Avogadri; Roberta Zappasodi; Arvin Yang; Sadna Budhu; Nicole Malandro; Daniel Hirschhorn-Cymerman; Shakuntala Tiwari; Maureen F Maughan; Robert Olmsted; Jedd D Wolchok; Taha Merghoub
Journal:  Cancer Immunol Res       Date:  2014-02-26       Impact factor: 11.151

3.  Viral vectors for vaccine applications.

Authors:  Youngjoo Choi; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2013-07-03

4.  New applications of alphavirus-based expression vectors.

Authors:  M Boorsma; D Koller; W A Renner; M F Bachmann
Journal:  Cytotechnology       Date:  2001-05       Impact factor: 2.058

5.  Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity.

Authors:  Francesca Avogadri; Taha Merghoub; Maureen F Maughan; Daniel Hirschhorn-Cymerman; John Morris; Erika Ritter; Robert Olmsted; Alan N Houghton; Jedd D Wolchok
Journal:  PLoS One       Date:  2010-09-10       Impact factor: 3.240

6.  Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene--a phase I/II clinical protocol.

Authors:  H Ren; T Boulikas; K Lundstrom; A Söling; P C Warnke; N G Rainov
Journal:  J Neurooncol       Date:  2003 Aug-Sep       Impact factor: 4.130

7.  Alphaviruses in gene therapy.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2009-04-21       Impact factor: 5.818

Review 8.  Gene therapy for carcinoma of the breast: Genetic immunotherapy.

Authors:  T V Strong
Journal:  Breast Cancer Res       Date:  1999-12-17       Impact factor: 6.466

Review 9.  Alphaviruses in gene therapy.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2015-05-07       Impact factor: 5.048

Review 10.  Alphavirus-based vaccines.

Authors:  Kenneth Lundstrom
Journal:  Viruses       Date:  2014-06-16       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.